Tarek Hamouda, MD, PhD, MBA, Director of Vaccine Research, NanoBio Corp.

Dr. Hamouda joined the University of Michigan in 1997and led the team for the development of topical antimicrobial nanoemulsion under the direction of Dr. James R. Baker Jr. In 2001 he moved to NanoBio Corp, and continued his work to commercialize the nanoemulsions. In 2006 he switched to the development of nanoemulsion vaccine adjuvants for intranasal influenza vaccine. Currently, Dr. Hamouda manages the preclinical development of the nanoemulsion adjuvanted intranasal vaccine program. His current work is focused on RSV and genital herpes vaccines. Dr. Hamouda received his MD and PhD from the Faculty of Medicine, Cairo University and an MBA from Michigan State University.